CN101899051B - 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof - Google Patents
1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof Download PDFInfo
- Publication number
- CN101899051B CN101899051B CN 201010176290 CN201010176290A CN101899051B CN 101899051 B CN101899051 B CN 101899051B CN 201010176290 CN201010176290 CN 201010176290 CN 201010176290 A CN201010176290 A CN 201010176290A CN 101899051 B CN101899051 B CN 101899051B
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyridine
- chromene
- oxo
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*Ic(cc1Oc(c2c3)nc(*)c3C(*)=O)ccc1C2=O Chemical compound C*Ic(cc1Oc(c2c3)nc(*)c3C(*)=O)ccc1C2=O 0.000 description 3
- ZDLRECFXNNTJSE-UHFFFAOYSA-N CCNC(c(c(C)n1)cc2c1Oc(cccc1)c1C2=O)=O Chemical compound CCNC(c(c(C)n1)cc2c1Oc(cccc1)c1C2=O)=O ZDLRECFXNNTJSE-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses 1-azaxanthone-3-formamide compounds as well as a preparation method and an application thereof, relating to the field of medicine. The compounds have certain antitumor effect. In particular, the compounds show good selective toxicity toward ambulant breast cancer cells, and provide a basis for developing an antitumor drug with high effect, low toxicity and strong specificity.
Description
Technical field
The present invention relates to medical technical field, more specifically, the present invention relates to a class 1-azepine xanthone-3-Carbox amide, the invention still further relates to preparation method and the application in the preparation antitumour drug thereof of this compounds.
Background technology
Malignant tumour is one of principal disease of serious threat human life and quality of life.According to 2007 data that the end of the year, the Ministry of Health announced, malignant tumour has become first cause of the death of China urban and rural residents.In recent years, chemotherapy of tumors has been obtained sizable progress, the tumour patient survival time obviously prolongs, particularly to having had than quantum jump the treatment of leukemia, malignant lymphoma etc., but treatment the most serious, that account for the solid tumor (comprise lung cancer, liver cancer, bladder cancer and colorectal carcinoma etc.) of malignant tumour more than 90% still fails to reach promising result to the harm humans life and health.
Along with the progress at full speed of life science, tumour mechanism is progressively illustrated, and the inhibition tumor growth factor in succession occurred, intervene the tumor signal conduction, has suppressed the new direction such as tumor-blood-vessel growth and inducing apoptosis of tumour cell; But because the pathogenesis of malignant tumour is very complicated, clinical practice in recent years shows that they only have with the cell toxicity medicament combined utilization and just can obtain preferably clinical efficacy.Therefore, as the drug screening target, find that selectively acting is significant in the new type anticancer medicine of efficient, the low toxicity of specific target spot, high specificity with key enzyme relevant with differentiation and proliferation in the tumour cell.
Topoisomerase I (Top1) has become one of crucial target enzyme of design new type anticancer medicine in recent years.It is the indispensable enzyme of cells survival, the whole process of participate in dna replication dna, transcribing, recombinate, repairing; And in the kinds of tumor cells especially the content of the Top1 such as lung cancer, cancer of the stomach, colorectal carcinoma, ovarian cancer apparently higher than normal cell.These all so that Top1 inhibitor class medicine not only curative effect is high, antitumor spectra is wide, and tumour cell is also had good selectivity, now classified as one of six large series antineoplastic medicaments of primary study by National Cancer Institute.
In all kinds of Top1 inhibitor, the research of camptothecine (CPT) analog derivative is the most deep, also is the most classical specific inhibitor of Top1.In this compounds, irenotecan (CPT-11) and topotecan are successfully gone on the market, and are used to the treatment of metastatic colorectal cancer and obstinate ovarian cancer etc., have obtained good curative effect.Yet also there is following outstanding problem in this compounds: 1) internal metabolism is unstable, and active essential E cyclic lactone structure is hydrolyzed into carboxylate form too quickly in human body, and carboxylate form is not only invalid to Top1, and easilier is combined with human serum albumin; 2) Top1 cutting mixture (Top1cc) time that need to keep a fixed length just can be converted into dna damage, however camptothecine be easy to dissociate from Top1cc, must prolong quiet time when therefore using camptothecine clinically; 3) poorly water-soluble, the five rings conjugate planes structure of camptothecine uniqueness has stronger hydrophobicity, causes it water-soluble relatively poor; 4) there is certain toxic side effect in camptothecine, such as from Leukopenia, feel sick, vomiting etc., limited safe dose and and then limited curative effect of medication; 5) resistance, the now camptothecine of existing several Top1 tolerance mutant strain report, modal have an Asn722, and the sudden change of Arg364 etc. all can cause the chemical sproof generation of camptothecine.
Non-camptothecin Top1 inhibitor has become in recent years anticarcinogen study hotspot.The Indolocarbazole compounds is to study at present a comparatively deep class, J-107088 in this compounds (Edotecarin) has entered clinical study, yet there are some researches show that this compounds is not the specific inhibitor of Top1, also have the activity of arrestin kinase c or check point kinase c hk-1.In addition, LuotonineA, LamellarinD separate the Top1 inhibitor that obtains from nature in recent years, but mostly there are the problems such as complex structure, poor specificity, toxic side effect are larger in they, at present clinical widely use still only have camptothecin antineoplastic agents.
In order to find the Top1 inhibitor of brand new type, we have carried out the virtual high flux screening research of Top1 inhibitor in earlier stage, successfully found several quasi-medicated properties good, without the lead compound of potential carinogenicity.Investigate based on activity, novelty and binding molecule graphics, we finally selected the purchase obtain that part of compounds presses down enzyme and cytotoxic activity is tested, the result shows: we find that first 1-azepine xanthone-3-Carbox amide has the activity of very strong inhibition Top1, significantly be better than the marketed drug topotecan, the cytotoxic activity test result shows that logarithm kind tumour cell has shown certain anti-tumor activity.Molecular Docking Study shows that such lead compound can form two hydrogen bond actions with the crucial avtive spot residue A rg364 that we identify the Topo I target enzyme of discovery in earlier stage, amide group on the side chain can form with the cytosine(Cyt) in DNA cleavage site downstream on the target enzyme+1 optionally effect, this has greater advantages so that this compounds is compared with existing Top1 inhibitor, is expected to overcome well the resistance problem of existing antitumor drug.
Need explanation, although this compounds compound can have been bought and obtains individually, the document the inside do not announce physico-chemical property, the preparation method of this compounds, and more this compounds can not be used for antineoplastic report.Therefore, our the 1-azepine xanthone found first-3-Carbox amide has represented the active compound for anti tumor of a class brand new.
Summary of the invention
The present invention seeks to for a class 1-azepine xanthone-3-Carbox amide is provided, or its pharmacy acceptable salt.The present invention discloses preparation method, medical use and the composition of this compounds.
The present invention is according to our the primer structure that obtains of virtual high flux screening in early stage, further designed, synthesized the derivative of this compounds, active testing to kinds of tumor cells shows, this compounds has certain anti-tumor activity, it is worthy of note especially, this compounds has shown good selective toxicity to metastatic breast cancer cell, and the antitumor drug of, low toxicity efficient for being developed as, high specificity is laid a good foundation.
1-azepine xanthone of the present invention-3-Carbox amide structure is shown in logical formula I:
Or its pharmacy acceptable salt, wherein, R
1The position of substitution can be positioned at 6 to 9, can be single, double or polysubstituted, R
1Be the arbitrary class in the following groups: a) hydrogen; B) the straight or branched alkoxyl group of C1-8; C) the straight or branched alkyl of C1-8; D) halogen; M) methylene-dioxy;
R
2, R
3Represent independently following groups: the alkyl of the straight or branched of hydrogen, C1-8, replacement or unsubstituted aryl methylene, alkoxyl group, nitro, amino, the hydroxyl of the straight or branched of the described alkyl that is substituted by the straight or branched of hydrogen, halogen, C1-8, C1-8; Or R
2, R
3Form together by 3 to 7 CH
2The chain that the unit connects to form;
R
4Straight or branched alkyl for hydrogen, C1-8.
In the further preferred embodiment of the present invention, above-mentioned 1-azepine xanthone-3-Carbox amide is worked as R
1Replace and 7 when being fluorine, chlorine R for single
2And R
3Combination can not be diethyl, the tertiary butyl, benzyl, p-chlorobenzyl; Work as R
1Replace and 7 when being hydrogen R for single
2And R
3Combination can not be benzyl, p-chlorobenzyl; Work as R
1Replace and 7 when being methyl R for single
2And R
3Combination can not be the tertiary butyl, benzyl, p-chlorobenzyl.
Further, above-mentioned 1-azepine xanthone-3-Carbox amide, R
1Be substituted by single replacement, be preferably 7 single replacements.
In the preferred embodiment of the present invention, above-mentioned 1-azepine xanthone-3-Carbox amide, R
2And R
3Be combined as and replace or unsubstituted aryl methylene, alkoxyl group, nitro, amino, the hydroxyl of the straight or branched of the described alkyl that is substituted by the straight or branched of hydrogen, halogen, C1-8, C1-8; Or R
2, R
3Form together by 3 to 7 CH
2The chain that the unit connects to form.Described aryl methylene is preferably benzyl, and further the replacement on the aryl methylene is preferably hydrogen or halogen.
In the preferred embodiment of the present invention, described 1-azepine xanthone-3-Carbox amide, R
4Be preferably methyl.
Aryl of the present invention is that remaining atomic group is called aryl after removing a hydrogen atom in the aromatic hydrocarbon molecule.Aromatic hydrocarbon is the compound that a class has aromaticity, its stable chemical nature, be difficult for addition, be difficult for oxidation, replace easily and the unusual stable characteristic of carbocyclic ring, be different from the character of general saturated compound, comprising: 1) mononuclear aromatics, only contain a phenyl ring in the molecule, such as benzene, toluene, ethylbenzene, vinylbenzene etc.; 2) polycyclic aromatic hydrocarbons contains the phenyl ring more than 2 or 2 in the molecule, such as biphenyl, naphthalene, anthracene, phenanthrene etc.; 3) non-benzene aromatic hydrocarbons does not contain phenyl ring in the molecule, but contains structure and the character aromatic hydrocarbons similar to phenyl ring, and has the characteristic of aromatics, such as cyclopentadienide anion etc.
Described substituted aryl refers to that the hydrogen atom on the aryl is replaced the group that obtains by other substituting group.
In an embodiment of the present invention, described 1-azepine xanthone-3-Carbox amide, each substituted radical make up to comprise and are not limited to following table:
Another object of the present invention has provided the preparation method of above-mentioned 1-azepine xanthone-3-benzamide type, comprises the following steps:
(1) preparation 3-cyano group-4-benzopyrone (II)
First DMF and phosphorus oxychloride are reacted half an hour at 0 ℃, add again the hydroxy acetophenone (I) that replaces, add again oxammonium hydrochloride behind the stirring at room reaction 4h and continue to react 6h, generate 3-cyano group-4-benzopyrone (II);
(2) preparation 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III)
3-cyano group-4-benzopyrone (II), methyl aceto acetate and piperidines are refluxed in ethanol, generate 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III);
(3) preparation 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV)
With 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III) is at 50%H
2Reflux in the SO4-AcOH mixing acid, generate 2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV);
(4) preparation 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxamide (V)
With 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV) is dissolved among the DMF, the dichloromethane solution that under 0 ℃, adds respectively DCC and HOBt, add amine after the stirred for several minute, stirring at room reaction 24h, generate 5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxamide (V).
Some 1-azepine xanthone-3-Carbox amide of the present invention can be prepared as according to ordinary method the form of the salt of its pharmacy acceptance.Comprise its inorganic acid salt and organic acid salt: mineral acid includes, but is not limited to hydrochloric acid, sulfuric acid, phosphoric acid, bisphosphate, Hydrogen bromide, nitric acid etc.; Organic acid includes, but is not limited to acetic acid, toxilic acid, fumaric acid, tartrate, succsinic acid, lactic acid, tosic acid, Whitfield's ointment, oxalic acid etc.
Compound of the present invention has good anti-tumor activity, they can be used for the treatment of tumour, comprise the cancer that the positions such as esophagus, stomach, intestines, rectum, oral cavity, pharynx, larynx, lung, colon, mammary gland, uterus, uterine endometrium, ovary, prostate gland, testis, bladder, kidney, liver, pancreas, bone, reticular tissue, skin, eye, brain and central nervous system occur, and thyroid carcinoma, leukemia, Huo Jiejinshi disease, lymphoma and myelomatosis etc.Preferably, the tumour for the treatment of is mammary cancer, more preferably, is metastatic mammary cancer.
The pharmacologically active of 1-azepine xanthone of the present invention-3-Carbox amide makes it can be for the preparation of antitumor, antimycotic and antiviral, therefore the present invention also comprises with these compounds or its pharmacologically acceptable salts pharmaceutical composition as activeconstituents, also contain the carrier of pharmaceutically accepting in this pharmaceutical composition, can be solid form or liquid form, described pharmaceutical dosage form can be tablet, capsule, powder agent, granule, suspensoid or injection.
Embodiment
Below in conjunction with embodiment the present invention is done specific descriptions, but the following example should not regarded limitation of the scope of the invention as.
The preparation of embodiment 1:3-cyano group-4-benzopyrone (II)
In flask at the bottom of the garden, add DMF (20mL) and POCl
3(12mL, 0125mol) is at 0 ℃ of lower stirring reaction 0.5h.In 0 ℃ of lower o-hydroxyacetophenone (4.25g, 0.031mol), room temperature reaction 4h of adding.Reaction adds CH after finishing
2Cl
2The 45mL dilution is chilled to 0 ℃, adds DMF solution (the 6.5g H of oxammonium hydrochloride again
2NOHHCl is dissolved among the 20mL DMF), stirring at room reaction 24h.Add water 35mL dilution after reaction finishes, (3 * 25mL), organic layer is used 10%NaHCO more successively with dichloromethane extraction
3Solution and saturated nacl aqueous solution washing.Anhydrous Na
2SO
4Drying is filtered, and the filtrate evaporate to dryness gets yellow solid.Recrystallizing methanol gets the brilliant 3.2g of colourless needle-like, yield 60.4.
1H-NMR(300MHz，CDCl
3)δ：7.53(1H，t，6-H)，7.55(1H，d，8-H)，7.78(1H，t，7-H)，8.25(1H，d，5-H)，8.40(1H，s，2-H)；ESI-MS(m/z)：210(M
++H+Na)；IR(KBr)cm
-1：2241，1662；m.p.176-178℃(lit.177-178℃)。
Embodiment 2:2-methyl-5-oxygen-5H-[1] preparation of chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III)
Get 3-cyano group-4-benzopyrone (II) (3.42g, 0.02mol), methyl aceto acetate (2.60g, 0.02mol) and piperidines 4mL, in 80mL ethanol, reflux.Stop after reaction finishes refluxing, cooling adds water 250mL dilution, filters the solid of separating out, and is washed to neutrality, drains, and gets red crude product.(the eluent: sherwood oil: ethyl acetate=20: 1), get white crystal 2.65g, yield 46.8% of purifying on silica gel chromatographic column.
1H-NMR(300MHz，CDCl
3)δ：1.45(3H，t，2’-CH
3)，2.91(3H，s，2-CH
3)，4.42(2H，q，1’-CH
2-)，7.52(1H，t，7-H)，7.65(1H，d，9-H)，7.85(1H，t，8-H)，8.28(1H，d，6-H)，9.16(1H，s，4-H)。ESI-MS(m/z)：282(M
++Na-K)；IR(KBr)cm
-1：1715，1655；m.p.151-152℃
Embodiment 3:2-methyl-5-oxygen-5H-[1] preparation of chromene [2,3-b] pyridine-3-carboxylic acid (IV)
With 2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III) (1.5g, 0.0053mol) adding 50%H
2SO
4-AcOH (1: 2) mixing acid 27mL, 130 ℃ of return stirring 3h.Reaction solution is poured in the 200mL water, separated out solid, filter, washing is drained and is obtained pale solid, uses DMF-H
2The O recrystallization gets white solid 1.21g, yield 91.3%.
1H-NMR(300MHz，d
6-DMSO)δ：2.85(3H，s，2-CH
3)，7.51(1H，t，7-H)，7.71(1H，d，9-H)，7.90(1H，t，8-H)，8.15(1H，d，6-H)，8.90(1H，s，4-H)，13.56(1H，br，-COOH)。ESI-MS(m/z)：256(M+H
+)；IR(KBr)cm
-1：3103，3066，1732，1644；m.p.290-295℃。
Embodiment 4:2-methyl-5-oxygen-5H-[1] preparation of chromene [2,3-b] pyridine-3-benzyl acid amides (V)
With 2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV) (1g, 0.004mol) is dissolved among the 20mL DMF, and frozen water is cooled to 0 ℃.Other takes by weighing DCC (0.87g, 0.0042mol) and HOBt (0.57g, 0.0042mol) is dissolved in respectively 50mLCH
2Cl
2In, under 0 ℃, add successively in the reaction solution, stir.In 0 ℃ of lower benzylamine (0.5mL, 0.004mol), stirred overnight at room temperature of adding.Reaction solution is used 5% citric acid, saturated NaHCO successively
3And water washing, the organic layer anhydrous Na
2SO
4Drying is filtered, and is concentrated into dried.Use ethyl alcohol recrystallization, get white crystal 0.72g, yield 53.1%.
1H-NMR (300MHz, CDCl
3) δ: 2.85 (3H, s, 2-CH
3), 4.70 (2H, d, 2 '-CH
2-), 6.50 (1H, br ,-NH-), 7.34～7.46 (6H, m, 3 '
And 7-H), 7.64 (1H, d, 9-H), 7.80 (1H, t, 8-H), 8.24 (1H, d, 6-H), 8.65 (1H, s, 4-H).ESI-MS(m/z)：345(M+H
+)，711(2M+Na
+)；IR(KBr)cm
-1：3270，1673，1638；m.p.215-216℃
The o-hydroxyacetophenone that remaining target compound replaces take different groups respectively and different amine repeat the step among the embodiment 1,2,3,4 as raw material, obtain different 2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-amides.Agents useful for same is commercially available analytical pure among the embodiment.
Chemical structure and the characterization data of the compound that the present invention's part has been synthesized are as follows.
Table 1 part is the structure of synthetic compound
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-methyl-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-methyl-3-amide
1H?NMR(300MHz，CDCl
3)δ2.83(3H，s，2-CH
3)，3.09(3H，d，2’-CH
3)，6.21(1H，br，-NH-)，7.45(1H，t，7-H)，7.60(1H，d，9-H)，7.80(1H，t，8-H)，8.25(1H，d，6-H)，8.62(1H，s，4-H)；ESI-MS(m/z)：269(M+H
+)；IR(KBr)cm
-1：3275，1673，1642；m.p.277-278℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-ethyl-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-ethyl-3-amide
1H?NMR(300MHz，CDCl3)δ：1.32(3H，t，3’-CH
3)，2.84(3H，s，2-CH
3)，3.55(2H，m，2’-CH
2)，6.05(1H，br，-NH-)，7.46(1H，t，7-H)，7.63(1H，d，9-H)，7.82(1H，t，8-H)，8.30(1H，d，6-H)，8.65(1H，s，4-H).ESI-MS(m/z)：283(M+H
+)；IR(KBr)cm
-1：3274，1670，1637；m.p.252-254℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-n-propyl-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-n-propyl-3-amide
1H?NMR(300MHz，CDCl3)δ1.04(3H，t，4’-CH
3)，1.68(2H，m，3’-CH
2)，2.80(3H，s，2-CH
3)，3.48(2H，m，2’-CH
2)，6.22(1H，br，-NH-)，7.48(1H，t，7-H)，7.61(1H，d，9-H)，7.81(1H，t，8-H)，?8.25(1H，d，6-H)，8.61(1H，s，4-H).ESI-MS(m/z)：295(M-H+)；IR(KBr)cm-1：3281，1671，1634；m.p.211-212℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-sec.-propyl-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-isopropyl-3-amide
1H?NMR(300MHz，CDCl3)δ：1.29(6H，dd，3’-CH
3×2)，2.84(3H，s，2-CH
3)，4.33(1H，m，2’-CH)，5.85(1H，br，-NH-)，7.47(1H，t，7-H)，7.64(1H，d，9-H)，7.82(1H，t，8-H)，8.32(1H，d，6-H)，8.63(1H，s，4-H)；ESI-MS(m/z)：297(M+H
+)；IR(KBr)cm-1：3274，1671，1636；m.p.240-241℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-normal-butyl-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-n-butyl-3-amide
1H?NMR(300MHz，CDCl
3)δ1.01(3H，t，5’-CH
3)，1.48(2H，m，4’-CH
2-)，1.66(2H，m，3’-CH
2-)，2.83(3H，s，2-CH
3)，3.52(2H，q，2’-CH
2-)，6.10(1H，br，-NH-)，7.46(1H，t，7-H)，7.63(1H，d，9-H)，7.81(1H，t，8-H)，8.28(1H，d，6-H)，8.63(1H，s，4-H)；ESI-MS(m/z)：311(M+H
+)；IR(KBr)cm
-1：3285，1671，1634；m.p.193-195℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-benzyl-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-benzyl-3-amide
1H?NMR(300MHz，CDCl
3)δ2.85(3H，s，2-CH
3)，4.70(2H，d，2’-CH
2-)，6.50(1H，br，-NH-)，7.34～7.46(6H，m，Ar-H)，7.64(1H，d，9-H)，7.80(1H，t，8-H)，8.24(1H，d，6-H)，8.65(1H，s，4-H)；ESI-MS(m/z)：345(M+H)
+，711(2M+Na)
+；IR(KBr)cm
-1：3270，1673，1638.m.p.215-216℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-chlorobenzyl)-3-acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-chlorobenzyl)-3-amide
1H-NMR(300MHz，CDCl
3)δ2.84(3H，s，2-CH
3)，4.65(2H，d，2’-CH
2-)，6.49(1H，br，-NH-)，7.34(4H，m，Ar-H)，7.45(1H，t，7-H)，7.61(1H，d，9-H)，7.80(1H，t，8-H)，8.24(1H，d，6-H)，8.64(1H，s，4-H)；ESI-MS(m/z)：379(M+H)
+，779(2M+Na)
+；IR(KBr)cm
-1：3308，1672，1637；m.p.240-241℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-piperidyl amide
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-3-piperidyl?amide
1H?NMR(300MHz，CDCl
3)δ1.55(2H，m，4’-CH
2-)，1.73(4H，m，3’，5’-CH
2-×2)，2.71(3H，s，2-CH
3)，3.26(2H，t，6’-CH
2-)，3.81(2H，t，2’-CH
2-)，7.46(1H，t，7-H)7.62(1H，d，9-H)，7.81(1H，t，8-H)，8.32(1H，d，6-H)，8.50(1H，s，4-H)；ESI-MS(m/z)：323(M+H)
+；IR(KBr)cm
-1：1651，1635；m.p.194-195℃
2-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-3-pyrryl acid amides
2-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-3-pyrrolidinyl?amide
1H?NMR(300MHz，CDCl
3)δ1.99(4H，m，3’，4’-CH
2-×2)，2.72(3H，s，2-CH
3)，3.28(2H，t，2’-CH
2-)，3.72(2H，t，5’-CH
2-)，7.48(1H，t，7-H)，7.62(1H，d，9-H)，7.80(1H，t，8-H)，8.30(1H，d，6-H)，8.56(1H，s，4-H)；ESI-MS(m/z)：309(M+H
+)，348(M+K)
+，639(2M+Na
+)；IR(KBr)cm
-1：1664，1629；m.p.159-160℃
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-methyl-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-methyl-3-amide
1H?NMR(300MHz，CDCl
3)δ2.50(3H，s，7-CH
3)，2.84(3H，s，2-CH
3)，3.08(3H，d，2’-CH
3)，6.11(1H，br，-NH-)，7.52(1H，d，9-H)，7.60(1H，d，8-H)，8.07(1H，s，6-H)，8.65(1H，s，4-H)；ESI-MS(m/z)：283(M+H)
+；IR(KBr)cm
-1：3277，1664，1643；m.p.279-281℃.
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-ethyl-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-ethyl-3-amide
1H-MR(300MHz，CDCl
3)δ：1.32(3H，t，CH
3)，2.50(3H，s，CH
3)，2.83(3H，s，CH
3)，3.55(2H，q，CH
2)，6.04(1H，br，NH)，7.52(1H，d，Ar-H)，7.61(1H，d，Ar-H)，8.08(1H，s，Ar-H)，8.64(1H，s，4-H)；ESI-MS(m/z)：297.46(M+H)
+；IR(KBr)cm
-13274，1672，1637；m.p.258-260℃
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-n-propyl-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-n-propyl-3-amide
1H?NMR(300MHz，CDCl
3)δ：1.05(3H，t，4’-CH
3)，1.71(2H，m，3’-CH
2)，2.50(3H，s，7-CH
3)，2.82(3H，s，2-CH
3)，3.49(2H，m，2’-CH
2)，6.11(1H，br，-NH-)，7.51(1H，d，9-H)，7.61(1H，d，8-H)，8.07(1H，s，6-H)，8.63(1H，s，4-H)；EI-MS(m/z)：351(M+K
+)，311(M+H
+)；IR(KBr)cm
-1：3284，1669，1635；m.p.221-222℃
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-sec.-propyl-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-isopropyl-3-amide
1H?NMR(300MHz，CDCl
3)δ1.33(6H，d，3’-CH
3×2)，2.51(3H，s，7-CH
3)，2.83(3H，s，2-CH
3)，4.32(1H，m，2’-CH)，5.85(1H，br，-NH-)，7.52(1H，d，9-H)，7.61(1H，d，8-H)，8.09(1H，s，6-H)，8.61(1H，s，4-H).ESI-MS(m/z)：311(M+H
+).IR(KBr)cm
-1：3298，1674，1633.m.p.254-256℃.
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-normal-butyl-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-n-butyl-3-amide
1H?NMR(300MHz，CDCl
3)δ1.01(3H，t，5’-CH
3)，1.48(2H，m，4’-CH
2-)，1.69(2H，m，3’-CH
2-)，2.49(3H，s，7-CH
3)，2.77(3H，s，2-CH
3)，3.51(2H，q，2’-CH
2-)，6.32(1H，br，-NH-)，7.48(1H，d，9-H)，7.60(1H，d，8-H)，8.01(1H，s，6-H)，8.57(1H，s，4-H).ESI-MS(m/z)：365(M+2H
++K
+).IR(KBr)cm
-1：3298，1674，1633.m.p.220-221℃.
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-benzyl-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-benzyl-3-amide
1H?NMR(300MHz，CDCl
3)δ2.47(3H，s，7-CH
3)，2.83(3H，s，2-CH
3)，4.69(2H，d，2’-CH
2)，6.51(1H，br，-NH-)，7.32～7.41(5H，m，Ar-H)，7.51(1H，d，9-H)，7.61(1H，d，8-H)，8.01(1H，s，6-H)，8.64(1H，s，4-H).ESI-MS(m/z)：739(2M+Na
+)，399(M+K
+)，359(M+H
+).IR(KBr)cm
-1：3270，1673，1633.m.p.248-249℃.
2-methyl-7-methyl-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-chlorobenzyl)-3-acid amides
2-methyl-7-methyl-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-chlorobenzyl)-3-amide
1H?NMR(300MHz，CDCl
3)δ2.49(3H，s，7-CH
3)，2.84(3H，s，2-CH
3)，4.65(2H，d，2’-CH
2)，6.53(1H，br，NH)，7.35(4H，d，Ar-H)，7.51(1H，d，9-H)，7.61(1H，d，8-H)，8.01(1H，s，6-H)，8.65(1H，s，4-H).ESI-MS(m/z)：393(M+H
+).IR(KBr)cm
-1：3277，1671，1635.m.p.245-246℃
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-n-propyl-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-n-propyl-3-amide
1H-NMR(300MHz，DMSO-d
6)δ0.93(t，3H，CH
3)，1.56(sext，2H，CH
2)，2.66(s，3H，CH
3)，3.24(m，2H，CH
2)，7.77(d，1H，J＝9.0Hz，Ar-H)，7.94(dd，1H，J
1＝8.7Hz，J
2＝2.4Hz，Ar-H)，8.07(s，1H，Ar-H)，8.46(s，1H，Ar-H)，8.71(br，1H，J＝5.4Hz，NH).ESI-MS(m/z)：329.63(M-H
-).IR(KBr)cm
-1：3283，1635，1671；m.p.256-258℃
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-sec.-propyl-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-isopropyl-3-amide
1H?NMR(300MHz，CDCl
3)δ1.33(6H，d，2CH
3)，2.85(3H，s，2-CH
3)，4.32(1H，m，CH)，5.80(1H，br，NH)，7.60(1H，d，9-H)，7.76(1H，d，8-H)，8.28(1H，s，6-H)，8.62(1H，s，4-H).ESI-MS(m/z)：331(M+H
+).IR(KBr)cm
-1：3282，1672，1637.m.p.280-281℃.
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-normal-butyl-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-n-butyl-3-amide
1H?NMR(300MHz，DMSO-d
6)δ0.92(t，3H，CH
3)，1.36(m，2H，CH
2)，1.51(m，2H，CH
2)，2.67(s，3H，CH
3)，3.27(m，2H，CH
2)，7.81(d，1H，J＝9.0Hz，Ar-H)，8.11(d，1H，J＝2.4Hz，Ar-H)，8.48(s，1H，Ar-H)，8.70(br，1H，J＝5.4Hz，NH).IR(KBr)cm
-1：3279，1698，1673.m.p.242-244℃.
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-hydroxyethyl-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-hydroxylethyl-3-amide
1H?NMR(300MHz，DMSO-d
6)δ1.24(m，2H，CH
2)，2.67(s，3H，CH
3)，3.54(m，2H，J＝5.7Hz，CH
2)，4.84(t，1H，J＝5.7Hz，OH)，7.81(d，1H，J＝9.0Hz，Ar-H)，7.99(dd，1H，J
1＝9.0Hz，J
2＝2.7Hz，Ar-H)，8.11(d，1H，J＝2.7Hz，Ar-H)，8.56(s，1H，Ar-H)，8.72(br，1H，J＝5.4Hz，NH).ESI-MS(m/z)：333.27(M+H
+).IR(KBr)cm
-1：3274，1681，1636.m.p.249-251℃.
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-benzyl-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-benzyl-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.68(s，3H，CH
3)，4.45(d，2H，J＝5.7Hz，CH
2)，7.28(dd，1H，J1＝8.4Hz，J
2＝4.2Hz，Ar-H)，7.37(d，4H，J＝5.2Hz，Ar-H)，7.78(d，1H，J＝9.0Hz，Ar-H)，7.94(dd，1H，J
1＝9.0Hz，J
2＝2.7Hz，Ar-H)，8.07(d，1H，J＝2.7Hz，Ar-H)，8.54(s，1H，Ar-H)，9.27(t，1H，J＝5.7Hz，NH).ESI-MS(m/z)：377.35(M-H)
-.IR(KBr)cm
-1：3269，1675，1634.m.p.268-270℃.
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-luorobenzyl)-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-flurobenzyl)-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.68(s，3H，CH
3)，4.48(d，2H，J
2＝6.0Hz，CH
2)，7.16-7.22(m，2H，Ar-H)，7.39-7.44(m，2H，Ar-H)，7.80(d，1H，J＝9.0Hz，Ar-H)，7.96(dd，1H，J
1＝9.0Hz，J
2＝2.7Hz，Ar-H)，8.10(d，1H，J＝2.4Hz，Ar-H)，8.56(s，1H，Ar-H)，9.25(t，1H，J＝6.0Hz，NH).ESI-MS(m/z)：395.62(M-H)
-.IR(KBr)cm
-1：3270，1677，1635.m.p.269℃(dec).
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-chlorobenzyl)-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-chlorobenzyl)-3-amide
1H?NMR(300MHz，CDCl
3)δ2.86(s，3H，CH
3)，4.64(d，2H，J＝5.7Hz，CH
2)，6.28(br，1H，NH)，7.32-7.39(m，4H，Ar-H)，7.59(d，1H，J＝8.7Hz，Ar-H)，7.75(dd，1H，J
1＝9.0Hz，J
2＝2.4Hz，Ar-H)，8.25(d，1H，J＝2.7Hz，Ar-H)，8.65(s，1H，Ar-H).ESI-MS(m/z)：411.64(M-H)
-.IR(KBr)cm
-1：3273，1674，1634.m.p.248℃(dec).
2-methyl-7-chloro-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-methyl-benzyl)-3-acid amides
2-methyl-7-chloro-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-methylbenzyl)-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.29(s，3H，CH
3)，2.68(s，3H，CH
3)，4.44(d，2H，J＝5.7Hz，CH
2)，7.17(d，2H，J＝8.1Hz，Ar-H)，7.26(d，2H，J＝8.1Hz，Ar-H)，7.81(d，1H，J＝9.0Hz，Ar-H)，7.97(dd，1H，J
1＝9.0Hz，J
2＝2.7Hz，Ar-H)，8.11(d，1H，J＝2.7Hz，Ar-H)，8.54(s，1H，Ar-H)，9.23(br，1H，NH).ESI-MS(m/z)：391.74(M-H)
-.IR(KBr)cm
-1：3277，1675，1635.m.p.261℃(dec).
2-methyl-7-methoxyl group-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-normal-butyl)-3-acid amides
2-methyl-7-methoxy-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-n-butyl)-3-amide
1H?NMR(300MHz，CDCl
3)δ0.92(t，3H，CH
3)，1.40(m，2H，CH
2)，1.52(m，2H，CH
2)，2.67(s，3H，CH
3)，3.26(m，2H，CH
2)，3.95(s，3H，OCH
3)，7.10(dd，1H，J
1＝8.7Hz，J
2＝2.4Hz，Ar-H)，7.26(d，1H，J＝2.4Hz，Ar-H)，8.09(d，1H，J＝9.0Hz，Ar-H)，8.45(s，1H，Ar-H)，8.68(br，1H，J＝5.4Hz，NH).ESI-MS(m/z)：341.66(M+H)
+.IR(KBr)cm
-1：3280，1694，1634.m.p.248-250℃.
2-methyl-7-methoxyl group-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-benzyl-3-acid amides
2-methyl-7-methoxy-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-benzyl)-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.68(s，3H，CH
3)，3.94(s，3H，OCH
3)，4.50(d，2H，J＝5.7Hz，CH
2)，7.09(dd，1H，J
1＝9.0Hz，J
2＝2.4Hz，Ar-H)，7.24(d，1H，J＝2.4Hz，Ar-H)，7.28(d，1H，J＝4.5Hz，Ar-H)，7.37(d，4H，J＝4.5Hz，Ar-H)，8.08(d，1H，J＝9.0Hz，Ar-H)，8.53(s，1H，Ar-H)，9.23(br，1H，NH).ESI-MS(m/z)：373.72(M-H)
-.IR(KBr)cm
-1：3270，1663，1634.m.p.268-270℃.
2-methyl-7-methoxyl group-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-luorobenzyl)-3-acid amides
2-methyl-7-methoxy-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-flurobenzyl)-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.67(s，3H，CH
3)，3.95(s，3H，OCH
3)，4.47(d，2H，J＝6.0Hz，CH
2)，7.08-7.26(m，4H，Ar-H)，7.39-7.43(m，2H，Ar-H)，8.09(d，1H，J＝9.0Hz，Ar-H)，8.53(s，1H，Ar-H)，9.23(br，1H，J＝6.0Hz，NH).EI-MS(m/z)：393.72(M+H)
+.IR(KBr)cm
-1：3292，1716，?1662.m.p.295-297℃.
2-methyl-7-methoxyl group-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-chlorobenzyl)-3-acid amides
2-methyl-7-methoxy-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-chlorobenzyl)-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.67(s，3H，CH
3)，3.95(s，3H，OCH
3)，4.48(d，2H，J＝6.0Hz，CH
2)，7.10(dd，1H，J
1＝9.0Hz，J
2＝2.4Hz，Ar-H)，7.25(d，1H，J＝2.4Hz，Ar-H)，7.38-7.45(m，4H，Ar-H)，8.09(d，1H，J＝8.7Hz，Ar-H)，8.54(s，1H，Ar-H)，9.24(br，1H，J＝6.0Hz，NH).ESI-MS(m/z)：407.56M-H)
-.IR(KBr)cm
-1：3294，1716，1662.m.p.270℃(dec).
2-methyl-7-methoxyl group-5-oxygen-5H-[1] chromene [2,3-b] pyridine-N-(4-methyl-benzyl)-3-acid amides
2-methyl-7-methoxy-5-oxo-5H-[1]benzopyrano[2，3-b]pyridine-N-(4-methylbenzyl)-3-amide
1H?NMR(300MHz，DMSO-d
6)δ2.29(s，3H，CH
3)，2.67(s，3H，CH
3)，3.95(s，3H，OCH
3)，4.44(d，2H，J＝5.7Hz，CH
2)，7.10(dd，1H，J
1＝9.0Hz，J
2＝2.4Hz，Ar-H)，7.17(d，2H，J＝7.8Hz，Ar-H)，7.25(d，2H，J＝3.9Hz，Ar-H)，7.26(d，1H，J＝3.9Hz，Ar-H)，8.09(d，1H，J＝9.0Hz，Ar-H)，8.50(s，1H，Ar-H)，9.19(br，1H，NH).EI-MS(m/z)：389.61(M+H)
+.IR(KBr)cm
-1：3257，1662，1637.m.p.275-277℃.
Embodiment 5: the cytotoxicity of compound of the present invention
(1) experiment material and method:
1. experiment material
(1) experimental strain
This experiment has adopted 3 kinds of human cancer cell strains as the screening object, and this JEG-3 provides by Shanghai Institute of Pharmaceutical Industry's Pharmacology Lab.
1) human lung cancer cell A549
2) human colon cancer cell Colo205
3) human breast cancer cell MDA-MB-435
(2) nutrient solution is that RPMI1640+15%NBS+ is two anti-.Used full-automatic microplate reader model is: WellscanMK-2, production firm: Labsystems.Import 96 well culture plates etc.
2. experimental technique
The extracorporeal anti-tumor tumor activity adopts mtt assay.
Sample preparation: after DMSO (Merck) dissolving, add solution or uniform suspension that PBS (-) is made into 1000 μ g/ml, then with PBS (-) dilution that contains DMSO.
Nutrient solution: RPMI640+15%NBS+ is two anti-
Positive control medicine: hydroxycamptothecine
Experimental procedure is as follows:
Every hole adding concentration is 4～5 * 10 in 96 well culture plates
4The cell suspension 1000 μ l of individual/ml put 37 ℃, 5%CO
2In the incubator.Behind the 24h, add sample liquid, two multiple holes are established in 10 μ l/ holes, and 37 ℃, 5%CO
2Effect 72h.Every hole adds the MTT solution 20 μ l of 5m g/ml, adds lysate behind the effect 4h, and put in the incubator in 100 μ l/ holes, surveys the 570nmOD value with the full-automatic microplate reader of MK-2 after the dissolving.
(2) experimental result
Table 2.29 compound is to the in-vitro multiplication restraining effect of human body tumour cell
Example 6: topoisomeraseⅠinhibitory property test
Use literature method (Kingsbury WD, Boehm JC, Jakas DR, et al.J Med Chem, 1991,34,98-107), part of compounds has been carried out the topoisomeraseⅠinhibitory property test, found that they have the activity of good inhibition Top1 in the 0.01-100uM scope.
To sum up, the compounds of this invention has certain antitumor action, it is worthy of note especially, this compounds has shown good selective toxicity to metastatic breast cancer cell, the antitumor drug of, low toxicity efficient for being developed as, high specificity is laid a good foundation, and has good exploitation and is worth.1-azepine xanthone of the present invention-3-Carbox amide is representing the compound with anti-tumor activity of a class brand new, and this is for furtheing investigate and developing new antitumor drug and opened up new approach and direction.
Claims (6)
1. a class 1-azepine xanthone-3-Carbox amide is selected from:
2. the preparation method of 1-azepine xanthone claimed in claim 1-3-Carbox amide may further comprise the steps:
(1) preparation 3-cyano group-4-benzopyrone (II)
First DMF and phosphorus oxychloride are reacted half an hour at 0 ℃, add again the hydroxy acetophenone (I) that replaces, add again oxammonium hydrochloride behind the stirring at room reaction 4h and continue to react 6h, generate 3-cyano group-4-benzopyrone (II);
(2) preparation 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III)
3-cyano group-4-benzopyrone (II), methyl aceto acetate and piperidines are refluxed in ethanol, generate 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III);
(3) preparation 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV)
With 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid ethyl ester (III) is at 50%H
2SO
4Reflux in-AcOH the mixing acid, generate 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV);
(4) preparation 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxamide (V)
With 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxylic acid (IV) is dissolved among the DMF, the dichloromethane solution that under 0 ℃, adds respectively DCC and HOBt, add amine after the stirred for several minute, stirring at room reaction 24h, generate 2-methyl-5-oxo-5H-[1] chromene [2,3-b] pyridine-3-carboxamide (V);
Wherein, definition in each symbol in the formula such as the claim 1.
3. the 1-azepine xanthone of a class shown in general formula (I)-3-Carbox amide or its pharmacy acceptable salt application in the preparation antitumor drug:
Wherein, R
1The position of substitution can be positioned at 6 to 9, can be single, double or polysubstituted, R
1Be the arbitrary class in the following groups: a) hydrogen; B) the straight or branched alkoxyl group of C1-8; C) the straight or branched alkyl of C1-8; D) halogen; M) methylene-dioxy;
R
2, R
3Represent independently following groups: the alkyl of the straight or branched of hydrogen, C1-8, replacement or unsubstituted benzyl, alkoxyl group, nitro, amino, the hydroxyl of the straight or branched of the described alkyl that is substituted by the straight or branched of halogen, C1-8, C1-8; Or R
2, R
3Form together by 3 to 7 CH
2The chain that the unit connects to form;
R
4Straight or branched alkyl for hydrogen, C1-8.
4. according to the application of formula claimed in claim 3 (I) compound or its salt at the preparation antitumor drug, it is characterized in that tumour is mammary cancer.
5. according to the application of formula claimed in claim 3 (I) compound or its salt at the preparation antitumor drug, it is characterized in that tumour is metastatic breast cancer.
6. a composition contains any 1-azepine xanthone-3-Carbox amide claimed in claim 1 or its pharmacy acceptable salt and reaches the carrier of pharmaceutically accepting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010176290 CN101899051B (en) | 2010-05-17 | 2010-05-17 | 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010176290 CN101899051B (en) | 2010-05-17 | 2010-05-17 | 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101899051A CN101899051A (en) | 2010-12-01 |
| CN101899051B true CN101899051B (en) | 2013-03-20 |
Family
ID=43225007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010176290 Expired - Fee Related CN101899051B (en) | 2010-05-17 | 2010-05-17 | 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101899051B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104610219B (en) * | 2015-01-14 | 2016-08-24 | 云南民族大学 | A kind of xanthones compound with oxidation isopentene group and its preparation method and application |
| CN111961046B (en) * | 2020-08-12 | 2021-09-07 | 上海诺精生物科技有限公司 | Compound for improving sensitivity of PCa drug-resistant cells to antagonist and application thereof |
| CN112010852B (en) * | 2020-08-12 | 2021-09-07 | 上海诺精生物科技有限公司 | Compound for inhibiting PCa cell transfer and application |
| CN113200989B (en) * | 2021-05-18 | 2022-06-21 | 云南民族大学 | Preparation method and application of chromone alkaloid compound |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0102175A1 (en) * | 1982-08-20 | 1984-03-07 | Takeda Chemical Industries, Ltd. | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use |
| WO2007008541A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2008020269A2 (en) * | 2005-12-13 | 2008-02-21 | Supratek Pharma, Inc. | A method of treating tumors with azaxanthones |
-
2010
- 2010-05-17 CN CN 201010176290 patent/CN101899051B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0102175A1 (en) * | 1982-08-20 | 1984-03-07 | Takeda Chemical Industries, Ltd. | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use |
| WO2007008541A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2008020269A2 (en) * | 2005-12-13 | 2008-02-21 | Supratek Pharma, Inc. | A method of treating tumors with azaxanthones |
Non-Patent Citations (2)
| Title |
|---|
| G.Jagath Reddy et.al..A mild, one-pot synthesis of 3-cyano-4-benzopyrones from 2-hydroxyacetophenones.《Tetrahedron Letters》.2004,第45卷(第4期),第847-848页. * |
| G.JagathReddyet.al..Amild one-pot synthesis of 3-cyano-4-benzopyrones from 2-hydroxyacetophenones.《Tetrahedron Letters》.2004 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101899051A (en) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102311434B (en) | Evodiamine compounds, preparation method thereof and application thereof | |
| CN102250000A (en) | Indenoquinolinone compounds, and preparation method and application thereof | |
| CN102070595A (en) | Substituted benzoxanthone type compound and application thereof | |
| Zhu et al. | Synthesis and structure-activity relationships study of α-aminophosphonate derivatives containing a quinoline moiety | |
| CN103601670A (en) | Piplartine analogue, and preparation method and application thereof | |
| CN101899051B (en) | 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof | |
| WO2013178021A1 (en) | Pyrrole [2, 1-f][1, 2, 4] triazine derivative and antitumor effect thereof | |
| CN110156822B (en) | Naphthol-phenylboronic acid compound and preparation method and application thereof | |
| JP2021526560A (en) | Camptothecin derivatives and their preparation methods and uses | |
| CN109438522A (en) | 5 FU 5 fluorouracil-platinum (IV) complex, intermediate, preparation method and application | |
| CN104926792A (en) | Metronidazole derivative and preparing method and application thereof | |
| CN102731493B (en) | Anti-tumor compound containing benzothiazole heterocyclic structure and application thereof | |
| CN112479974B (en) | Preparation and application of 3-carbonyl-2, 3' -bisindole nitrogen oxide derivative | |
| CN102746281B (en) | 4-1,2,3-triazole-coumarin derivative and its preparation method and application | |
| CN101332198B (en) | Pharmaceutical use of 6-aryl-3-substituted carbonyl pyridine compound | |
| CN102688234B (en) | Indolone derivatives is as the Synthesis and application of RSK2 inhibitor | |
| CN108358894B (en) | Compound for inhibiting histone acetyltransferase as well as preparation method and application thereof | |
| CN106588920B (en) | 1,3- diazacyclos simultaneously [1,2-a] quinolines and preparation method thereof and antitumor application thereof | |
| CN112279863A (en) | Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof | |
| CN109824640A (en) | A kind of coumarin kind compound and its pharmaceutical composition, preparation method and application | |
| CN115894520A (en) | Macrocyclic K-RAS G12C inhibitor, preparation method and pharmaceutical application thereof | |
| CN100484940C (en) | Water-soluble camptothecine derivative and its preparation process and application thereof | |
| Li et al. | Design and synthesis of luotonin A-derived topoisomerase targeting scaffold with potent antitumor effect and low genotoxicity | |
| CN107011312A (en) | Jungermanniaceae D nitrogen containing derivative and preparation method thereof and the purposes in treatment tumor disease | |
| CN104292211A (en) | Desloratadine nitric oxide donor, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Song Yunlong Inventor after: Chen Qianqian Inventor after: Zhang Ling Inventor after: Fu Xiaodan Inventor after: Qi Yunpeng Inventor after: Zhang Wannian Inventor after: Zhu Ju Inventor after: Zhou Youjun Inventor after: Lv Jiaguo Inventor after: Liu Qian Inventor before: Song Yunlong Inventor before: Zhang Ling Inventor before: Fu Xiaodan Inventor before: Qi Yunpeng Inventor before: Zhang Wannian Inventor before: Zhu Ju Inventor before: Zhou Youjun Inventor before: Lv Jiaguo |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SONG YUNLONG ZHANG LING FU XIAODAN QI YUNPENG ZHANG WANNIAN ZHU JU ZHOU YOUJUN LV JIAGUO TO: SONG YUNLONG ZHANG LING FU XIAODAN QI YUNPENG ZHANG WANNIAN ZHU JU ZHOU YOUJUN LV JIAGUO LIU QIAN CHEN QIANQIAN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 Termination date: 20150517 |
|
| EXPY | Termination of patent right or utility model |